Oncology Business Management | Specialty

AI Integration and Systemic Reform Are Needed to Balance Resource Protection With Timely Access to Treatment

October 7th 2025

Emerging technologies and process reconsiderations may alleviate time and resource stressors oncology teams face when appealing patient insurance denials.

FDA Approval of Intravesical Mitomycin in NMIBC Follows ODAC Debate on Need for Randomized Data

October 7th 2025

FDA’s Push for Faster Drug Reviews Intersects With Policy Shifts on EU-Imposed Tariffs

August 29th 2025

As the FDA aims to reduce drug review times, the 15% tariff rate imposed on pharmaceuticals from Europe could affect drug access in the oncology space.

Researchers Address the Barriers to Remote Breast Cancer Symptom Monitoring in the US

May 23rd 2025

Barriers in utilizing remote collection of patient-reported outcomes persist, although it has been proven to be effective in breast cancer.

Cardio-Oncology Investigations Begin to Uncover More Links Between CVD and Breast Cancer

February 26th 2025

For American Heart Month, cardiologist Amy M. Ahnert, MD, and oncologist Kevin T. Nead, MD, MPhil, unpacked the link between CVD and breast cancer.

Transparency and Consolidation Issues Hamper 340B Program in Cancer Care

December 30th 2024

Since it's implementation in 1992, the aim of the 340B Drug Pricing Program has been to offer low-income and underserved patient populations with cancer and other diseases expanded access to affordable medications by selling drugs at discounted prices to eligible centers.

Education, Telehealth, and Access Initiatives Aim to Improve Cancer Care for Veterans

November 26th 2024

Manali I. Patel, MD, MPH, MS, details several interventions developed to better serve veterans with cancer who are experiencing economic, social, and geographic barriers to care.

Category 1 Recommendation of Ribociclib Plus an AI Represents Huge Advancement in Breast Cancer

November 22nd 2024

Jairam Krishnamurthy, MD, FACP, details what to take into consideration when implementing 2024 Breast Cancer NCCN guideline changes into everyday practice.

Revisit Every OncLive On Air Episode From October 2024

November 1st 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in October 2024.

Medicare Drug Price Negotiations Will Have Domino Effect for Community Oncology Practices

September 24th 2024

Medicare drug price negotiations may impact community oncology practices, leading to potential changes in drug access, reimbursement, and patient care strategies.

AI Is Poised to Influence Several Areas of Cancer Care With Some Fine-Tuning

September 23rd 2024

Krishnansu S. Tewari, MD, and Kimberly Futch, MBA, detail considerations with AI programs, and roles AI may have in early diagnosis, time reduction in the examination of scans, and more.

Medicare Drug Price Negotiation Program Will Result in Financial Burdens for Community Oncology Practices

September 5th 2024

Debra Patt, MD, PhD, MBA, FASCO, highlights considerations with financial burdens that will be placed on community providers and oncology practices.

A Decrease in Innovation Is a Large Concern With New IRA Policies in Oncology

September 4th 2024

Jeff Patton, MD, details considerations with the Medicare Drug Price Negotiation Program Draft Guidance and its effects in the community setting.

Vice President of COA Unpacks Effects of the Medicare Drug Price Negotiation Program in the Community

September 3rd 2024

Debra Patt, MD, PhD, MBA, FASCO, details how the Medicare Drug Price Negotiation Program Draft Guidance will affect community oncologists and practices.

Merck to Discontinue KEYNOTE-867 and KEYNOTE-630 Trials of Pembrolizumab in NSCLC, CSCC

August 29th 2024

The phase 3 KEYNOTE-867 and KEYNOTE-630 trials evaluating pembrolizumab in NSCLC and CSCC, respectively, have been discontinued by Merck.

Revisit Every OncLive On Air Episode From July 2024

July 31st 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in July 2024.

340B Drug Pricing Program Ostensibly Improves Cancer Care but Carries Unforeseen Consequences

July 22nd 2024

Kassem Faraj, MD, details the 340B Drug Pricing program and data from a study examining participation in the program for patients with advanced prostate cancer.

Carving Out a Career in Medical Education

July 16th 2024

Sam Brondfield, MD, MA, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses careers in medical education.

Revisit Every OncLive On Air Episode From June 2024

July 1st 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in June 2024.

Leveraging Managed Service Organizations to Provide More Affordable, Personalized Cancer Care

May 17th 2024

To combat the rising costs of cancer care, clinicians are partnering with managed service organizations to handle the business aspects of practice.